Skip to main content

Salesforce faces an underappreciated risk: Platform customers jumping ship like Veeva

One analyst thinks Salesforce won't be able to compete well with Veeva in life sciences after their broad-based agreement that bans competition ends in 2025.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.